Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

NCT05910710 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT05910710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05910710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Unknown status
Start date
March 2, 2023
Completion date
December 31, 2025
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant chemotherapy, pembrolizumab, triple negative breast cancer, tumor microenvironment